After another week of yield-paying sectors smashing all-time records while the high-tech heart of Wall Street remains depressed, other investors are starting to hum the refrain I started singing last week.
Money is flowing out of utilities, real estate and consumer staples back into more dynamic areas of the market. That’s an important distinction.
No matter what you hear, we aren’t facing a lot of fear right now. We’re dealing with a form of greed.
The Real Bubble Is Safety
Risk tolerances haven’t collapsed. Bond yields around the world have. And as money inches out of bonds in search of reasonable returns, yields in the stock market follow bond rates lower.
We talked last week about the premium risk-averse investors are paying for relief from recession anxiety without having to accept the negative inflation-adjusted income they’d get from Treasury bonds. Let’s bring a little more math to the table.
If prices are climbing 1.7 percent a year and the Fed won’t raise rates before inflation hits 2 percent, buying middle-term government debt will leave you with less purchasing power when those bonds mature than what you have now.
That’s only an acceptable strategy if you’ve abandoned hope for anything in the global markets doing better than breaking even. We’re naturally on the side of doing better.
So are most realistic investors who recognize that the world is a long way from the point where locking the doors against absolute disaster is the only move that makes sense. However, some moves only make sense because every other option has a worse outcome. That’s where I think utilities and consumer staples stocks are now. They’re not objectively bad as places to park cash ahead of an economic storm.
But when you see better alternatives, these sectors look bloated and on their way to outright bubble territory. Utilities, for example, usually command a slight premium because their dividends are about as reliable as it gets, and people will pay extra for that kind of clarity.
However, that premium has expanded a lot in the last few months. Three months ago, these stocks were available for 19.1X earnings against an 18.4X multiple for the S&P 500 as a whole.
As of last week, the S&P 500 valuation hasn’t changed while utilities are at the point where they cost 20.9X earnings to buy.
Admittedly, the sector still pays a 1 percent higher dividend yield than the S&P 500, but when you’re weighing whether to lock in 2.8 percent or 1.8 percent yield, nobody is reaping huge windfalls here.
But the real arbiter of value in a defensive portfolio is the amount of extra income investors can squeeze out of the stocks they pick while their money is parked.
With Treasury debt, the rate you lock in is the interest you’ll receive. The odds of a default are as close to zero as it gets. Everywhere else, you’re accepting a little risk that a company will run out of cash and cut its dividend or skip a payment.
Five-year bonds bottomed out at 1.26 percent at the end of 2008, when it looked like Wall Street’s world was ending and overnight lending rates were effectively zero. Back then, utilities paid 4.2 percent to reflect the elevated risk that these companies would fail to meet their shareholder obligations.
The spread naturally rose to roughly 3 percentage points. A lot of people were scared. What happened, of course, is that the sector didn’t even blink.
Likewise, we can track the spread between “defensive” yields and what investors get from the S&P 500. Normally, we expect utilities to pay 2.4% more than the broad market. The spread is now barely 1 percentage point wide.
There just isn’t a lot of room left there for more money to crowd into the sector before the risk curve breaks. Back in 2008, for example, the yield spread between utilities and the S&P 500 narrowed to barely 1.2 percentage point. We’re close to that historical limit now.
Does This Feel Like 2008?
I’m lingering on this math to give you a better sense of how the current rush to defense is distorted in any reasonable historical context. If the world right now feels like it did at the end of 2008, then locking in these abnormally low yields and compressed risk spreads makes sense as the best way to sidestep any significant economic threat.
Otherwise, the math doesn’t add up. The usual statistical indicators that accompany real fear in the market simply aren’t there.
To borrow a line from the Sherlock Holmes stories, the dog isn’t barking. Maybe there’s no dog.
And in that scenario, money soon will flow back out of overcrowded yield stocks into what are now underrated areas of the market. My GameChangers recommendations are already rebounding with a lot of room to keep the rally going.
Remember, locking in a yield means locking out a lot of upside. How high can utilities go, for example, when earnings in the sector are inching up 2 percent a year?
Growth stocks do a lot better. That’s how you stay ahead of inflation.
And until the market makes up its mind, we can make money simply riding the roller coaster. Click here now to watch my presentation about how you can profit in sideways markets, too.
Cannabis Corner: Cut Through the Hexo Haze
I think we’re seeing something like capitulation play out in Big Cannabis stocks. While that’s a healthy sign of firmer fundamentals over the horizon, investors simply need to weather the industry storms in the here and now.
Hexo Corp. (NYSE:HEXO) is this week’s sick canary in the cannabis field. Like many start-up companies, it’s growing fast and Wall Street has rewarded it for that growth. But when that growth falters, the punishments are severe.
With Hexo, the mood was already anxious after the chief financial officer quit suddenly because he was tired of commuting across Canada. Then the revenue warning hit.
Apparently, sales of pre-rolled cigarettes, sprays and enhanced cannabis products aren’t ramping up as fast as analysts wanted to see. They were looking for $25 million in sales this quarter. Hexo isn’t committing to more than $16 million.
And that simple confession triggered a blast of panic selling throughout the industry. In the last two days, Hexo is down 27 percent, losing $170 million in market capitalization to compensate for that $9 million in revenue that isn’t going to come in right away.
Naturally I think the reaction is overdone. We’re dealing with a company that didn’t even take in $5 million in the entirety of 2018 and is now on track to generate 9X that much revenue this year even after lowering its 4Q19 target.
What’s changed? The company investors were happy to hold above $4 because it was raising the top line 990 percent is now on sale below $3 to cover what’s shrunk to a mere 820 percent growth rate.
When a business is expanding this fast, these fluctuations aren’t even rounding errors in a marathon measured in years. A few good months or even weeks can get Hexo back on course and then those who sold at $4 will envy those who bought at $3.
For us, however, what’s important isn’t the fate of Hexo but what reaction to this little company says about broader market sentiment. People leaping to conclusions have dumped all cannabis stocks across the board.
And the results have been extreme. Hexo’s miss took roughly $3 billion in market cap away from the bigger cultivators we track like Canopy Growth Corp. (NYSE:CGC) and Aurora Cannabis Inc. (NYSE:ACB).
Since Hexo was only an $800 million stock, the industry has now lost far more money here than it would if the ambitious little start-up had simply gone bust. Fundamentally, that just doesn’t add up.
When the selling doesn’t match the fundamentals, irrational sentiment is in control. We’ve seen these stocks attract plenty of froth in the past. Now I suspect the mood has moved too far in the opposite direction.
After all, Hexo doesn’t blame a downswing in demand for its products. You can’t stand behind an 820 percent growth year if your market is actively deteriorating.
They blame delays. When those regulatory hurdles and retail bottlenecks resolve, they’ll get that lost $9 million back and more.
If not, someone in the industry will grab it instead. Maybe that will be one of the giants, in which case the contagious selling we saw this week is a true buying opportunity.
Either way, my Turbo Trader Marijuana Millionaire Portfolio is nimble enough to keep pivoting to the opportunities. Unlike most cannabis investors, we’ve booked our share of profits in the last few months. We’ll keep doing it.
Where does the Smart Money look for the best biotech stocks? Small- and mid-cap biotechs. They're the ones with the ability to transform the world, and bring investors transformational profits. To get free access to Hilary Kramer's latest report, 3 Biotech Breakthroughs To Bank On, simply tell us where to send it in the box below.